Literature DB >> 12810622

Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.

Kirsi Saukkonen1, Catherine Tomasetto, Kirsi Narko, Marie-Christine Rio, Ari Ristimäki.   

Abstract

Expression of cyclooxygenase-2 (Cox-2) is elevated in gastric adenocarcinomas and precursor lesions leading to this disease. Mice deficient for trefoil factor 1 (TFF1) develop a pyloric adenoma with full penetrance. Because inhibition of Cox-2 suppresses tumor growth in several animal models, we studied expression of Cox-2 and effect of a selective Cox-2 inhibitor celecoxib in gastrointestinal tissues of the TFF1-deficient mice. Cox-2 mRNA and protein were strongly expressed in the pyloric adenomas of the TFF1(-/-) mice as detected by in situ hybridization and immunohistochemistry. Nonneoplastic gastrointestinal tissues of wild-type or TFF1(-/-) mice expressed low or nondetectable levels of Cox-2. Celecoxib (1600 ppm p.o. for 3 months) caused ulceration and inflammation of the adenoma in all treated TFF1(-/-) mice (n = 7). This effect of the drug was adenoma specific, because no histological alterations were observed in the non-neoplastic gastric or intestinal tissues in the TFF1(-/-) or wild-type mice receiving the drug treatment. All untreated TFF1(-/-) mice had an adenoma (n = 7), but none demonstrated the combination of ulceration and inflammation. Our data show that Cox-2 is expressed in gastric adenomas of the TFF1(-/-) mice and suggest that inhibition of Cox-2 disturbs the integrity of the adenoma by promoting ulceration and inflammation. These findings support the effort to initiate clinical studies to investigate the effect of Cox-2 inhibitors as a chemotherapeutic modality for dysplasias of the stomach.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810622

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Interleukin-8, cyclo-oxygenase-2, and trefoil factor family 1 gene expression and their association with Helicobacter pylori infection in the remnant stomach.

Authors:  Chengzhong Xing; Shunji Kato; Norio Matsukura; Noriko Matsuda; Huimian Xu; En Takashi; Nobutaka Yamada; Zenya Naito; Takashi Tajiri
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.

Authors:  J Mrena; J-P Wiksten; S Nordling; A Kokkola; A Ristimäki; C Haglund
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 3.  Targeting the LKB1 tumor suppressor.

Authors:  Rui-Xun Zhao; Zhi-Xiang Xu
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 4.  Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis.

Authors:  Yun Shao; Kun Sun; Wei Xu; Xiao-Lin Li; Hong Shen; Wei-Hao Sun
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer.

Authors:  Johanna Mrena; Jan-Patrik Wiksten; Arto Kokkola; Stig Nordling; Ari Ristimäki; Caj Haglund
Journal:  Tumour Biol       Date:  2009-12-18

6.  Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Authors:  Natalia A Ignatenko; David G Besselsen; Upal K Basu Roy; David E Stringer; Karen A Blohm-Mangone; Jose L Padilla-Torres; Jose M Guillen-R; Eugene W Gerner
Journal:  Nutr Cancer       Date:  2006       Impact factor: 2.900

7.  Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Authors:  Photini F S Rice; Kevin G Ehrichs; Mykella S Jones; Hwudarw Chen; Chiu-Hsieh Hsu; Edward R Abril; Raymond B Nagle; David G Besselsen; Jennifer K Barton; Natalia A Ignatenko
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-08

Review 8.  Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.

Authors:  Takashi Fujimura; Tetsuo Ohta; Katsunobu Oyama; Tomoharu Miyashita; Koichi Miwa
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

9.  Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.

Authors:  Li-Jing Zhang; Shi-Yan Wang; Xiao-Hui Huo; Zhen-Long Zhu; Jian-Kun Chu; Jin-Cheng Ma; Dong-Sheng Cui; Ping Gu; Zeng-Ren Zhao; Ming-Wei Wang; Jun Yu
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

Review 10.  Trefoil Factor Family (TFF) Peptides and Their Links to Inflammation: A Re-evaluation and New Medical Perspectives.

Authors:  Werner Hoffmann
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.